|
Gene: TRIP10 |
Gene summary for TRIP10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TRIP10 | Gene ID | 9322 |
Gene name | thyroid hormone receptor interactor 10 | |
Gene Alias | CIP4 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15642 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9322 | TRIP10 | LZE4T | Human | Esophagus | ESCC | 3.46e-06 | -7.02e-02 | 0.0811 |
9322 | TRIP10 | LZE8T | Human | Esophagus | ESCC | 3.55e-03 | 4.39e-02 | 0.067 |
9322 | TRIP10 | LZE22D1 | Human | Esophagus | HGIN | 1.26e-05 | 1.31e-01 | 0.0595 |
9322 | TRIP10 | LZE24T | Human | Esophagus | ESCC | 3.48e-04 | 3.61e-01 | 0.0596 |
9322 | TRIP10 | LZE21T | Human | Esophagus | ESCC | 8.70e-07 | 8.11e-02 | 0.0655 |
9322 | TRIP10 | P1T-E | Human | Esophagus | ESCC | 2.85e-05 | 9.60e-01 | 0.0875 |
9322 | TRIP10 | P2T-E | Human | Esophagus | ESCC | 4.04e-14 | -6.35e-02 | 0.1177 |
9322 | TRIP10 | P4T-E | Human | Esophagus | ESCC | 1.61e-15 | 1.64e-02 | 0.1323 |
9322 | TRIP10 | P5T-E | Human | Esophagus | ESCC | 3.14e-18 | 2.77e-01 | 0.1327 |
9322 | TRIP10 | P8T-E | Human | Esophagus | ESCC | 1.85e-48 | 1.12e+00 | 0.0889 |
9322 | TRIP10 | P9T-E | Human | Esophagus | ESCC | 1.77e-07 | 5.76e-02 | 0.1131 |
9322 | TRIP10 | P10T-E | Human | Esophagus | ESCC | 7.58e-08 | 1.21e-01 | 0.116 |
9322 | TRIP10 | P11T-E | Human | Esophagus | ESCC | 2.45e-02 | 9.98e-02 | 0.1426 |
9322 | TRIP10 | P12T-E | Human | Esophagus | ESCC | 4.05e-17 | 1.21e-01 | 0.1122 |
9322 | TRIP10 | P15T-E | Human | Esophagus | ESCC | 2.16e-09 | 1.47e-01 | 0.1149 |
9322 | TRIP10 | P16T-E | Human | Esophagus | ESCC | 2.36e-14 | -1.02e-01 | 0.1153 |
9322 | TRIP10 | P17T-E | Human | Esophagus | ESCC | 2.46e-10 | 1.66e-01 | 0.1278 |
9322 | TRIP10 | P20T-E | Human | Esophagus | ESCC | 4.31e-11 | 2.22e-02 | 0.1124 |
9322 | TRIP10 | P21T-E | Human | Esophagus | ESCC | 4.53e-13 | 1.91e-01 | 0.1617 |
9322 | TRIP10 | P22T-E | Human | Esophagus | ESCC | 1.66e-08 | -1.82e-01 | 0.1236 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049108 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIP10 | deletion | Frame_Shift_Del | c.1004delN | p.Leu337TrpfsTer26 | p.L337Wfs*26 | Q15642 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
TRIP10 | deletion | Frame_Shift_Del | c.1011delN | p.Gly339AlafsTer24 | p.G339Afs*24 | Q15642 | protein_coding | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
TRIP10 | SNV | Missense_Mutation | rs148404026 | c.932N>A | p.Arg311Gln | p.R311Q | Q15642 | protein_coding | tolerated(0.17) | possibly_damaging(0.557) | TCGA-A5-A1OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
TRIP10 | SNV | Missense_Mutation | novel | c.245A>C | p.Asp82Ala | p.D82A | Q15642 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
TRIP10 | SNV | Missense_Mutation | rs147776897 | c.361N>T | p.Arg121Trp | p.R121W | Q15642 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRIP10 | SNV | Missense_Mutation | rs756625759 | c.640G>A | p.Asp214Asn | p.D214N | Q15642 | protein_coding | tolerated(0.45) | probably_damaging(0.955) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIP10 | SNV | Missense_Mutation | novel | c.170G>T | p.Arg57Ile | p.R57I | Q15642 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TRIP10 | SNV | Missense_Mutation | c.775N>A | p.Val259Met | p.V259M | Q15642 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TRIP10 | SNV | Missense_Mutation | novel | c.574N>A | p.Ala192Thr | p.A192T | Q15642 | protein_coding | tolerated(0.13) | probably_damaging(0.936) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIP10 | SNV | Missense_Mutation | rs556672884 | c.1490C>T | p.Pro497Leu | p.P497L | Q15642 | protein_coding | tolerated(0.09) | probably_damaging(0.992) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |